Noble Life Sciences - About the company
Noble Life Sciences is a seed company based in Woodbine (United States), founded in 2010 by Kenneth Carter. It operates as a Preclinical contract research organization offering standard GLP and non-GLP services. Noble Life Sciences has raised $335K in funding. The company has 115 active competitors, including 11 funded and 20 that have exited. Its top competitors include companies like TransCure bioServices, GenOway and InVivo Biosystems.
Company Details
Noble Life Sciences is a preclinical contract research organisation offering standard GLP and non-GLP services, including safety and efficacy testing, for the development of drugs, vaccines, and medical devices. They offer preclinical testing in a wide variety of mammalian species including rabbits, rats, mice, ferrets, guinea pigs, sheep, goats, domestic swine and mini pigs. Their services also include the derivation and maintenance of animal breeding colonies, animal housing and husbandry, the production of custom antibodies, and the development of disease and animal models. The company offers specialised services for oncology drug evaluation, polyclonal antibody production and vaccine development.
- Website
- noblelifesci.com
- Social
- Email ID
- *****@noblelifesci.com
Key Metrics
Founded Year
2010
Location
Woodbine, United States
Stage
Seed
Total Funding
$335K in 2 rounds
Latest Funding Round
Ranked
10th among 115 active competitors
Employee Count
41 as on Jul 31, 2026
Similar Companies
Sign up to download Noble Life Sciences' company profile
Noble Life Sciences's funding and investors
Noble Life Sciences has raised a total funding of $335K over 2 rounds. Its first funding round was on Mar 30, 2012. Its latest funding round was a Seed round on 2013 for $*****. 1 investor participated in its latest round. Noble Life Sciences has 5 institutional investors.
Here is the list of recent funding rounds of Noble Life Sciences:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
2013 | 8536 | Seed | 2269 | 4585 | 1504 | 8202 |
Mar 30, 2012 | 7535983 | Seed | 2555437 | 1964197 | 1160790 | 3889388 |
Access funding benchmarks and valuations. Sign up today!View details of Noble Life Sciences's funding rounds and investors
Noble Life Sciences' founders and board of directors
Founder? Claim ProfileThe founders of Noble Life Sciences is Kenneth Carter.
Here are the details of Noble Life Sciences' key team members:
- Kenneth Carter: Co-Founder and Chairman of Noble Life Sciences and founder of 1 other company. They serve on the board of 1 company.
View details of Noble Life Sciences's Founder profiles and Board Members
Noble Life Sciences' employee count trend
Noble Life Sciences has 41 employees as of Jul 26. Here is Noble Life Sciences's employee count trend over the years:
Uncover Noble Life Sciences' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Noble Life Sciences's Competitors and alternates
Top competitors of Noble Life Sciences include TransCure bioServices, GenOway and InVivo Biosystems. Here is the list of Top 10 competitors of Noble Life Sciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | TransCure bioServices 2012, Archamps (France), Series B | Developer of humanized animal models for preclinical studies | $3.58M | 59/100 | |
2nd | Provider of transgenic rodent models and customized cell lines for preclinical development | $11.6M | 58/100 | ||
3rd | InVivo Biosystems 2019, Eugene (United States), Series A | Provider of animal models for in-vivo analytical services | $8.16M | 46/100 | |
4th |  Magnitude Biosciences 2018, Durham (United Kingdom), Seed | Provider of early in vivo whole-organism high-throughput phenotypic screening and follow-up assays for drug discovery | $2.6M | 46/100 | |
5th | Alpha Genesis 2003, Yemassee (United States), Series B | Preclinical research services specializing in nonhuman primate models for therapy development | $12.5M | - | 45/100 |
6th | Animal models of neurological and psychiatric disorders for drug discovery | - | - | 40/100 | |
7th | Explora BioLabs 2004, San Diego (United States), Acquired | Provider of discovery pharmacology and vivarium services for biotechnology and pharmaceutical clients | - | 39/100 | |
8th | Fibrofind United Kingdom, Acquired | Provider of preclinical drug development research solutions for fibrotic diseases | - | - | 39/100 |
9th |  MPP Group, LLC 2016, United States, Acquired | Provider of injectable drug development and analytical testing services | - | - | 37/100 |
10th | Noble Life Sciences 2010, Woodbine (United States), Seed | Preclinical contract research organization offering standard GLP and non-GLP services | $335K | 37/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Noble Life Sciences's competitors? Click here to see the top ones
Noble Life Sciences's Investments and acquisitions
Noble Life Sciences has made no investments or acquisitions yet.
Reports related to Noble Life Sciences
Here is the latest report on Noble Life Sciences's sector:
News related to Noble Life Sciences
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Noble Life Sciences
Explore our recently published companies
- Marketing Agency - Deptford based, 2020 founded, Unfunded company
- Aquiyel Services - Houston based, 2020 founded, Public company
- B2clogin.com - 2017 founded, Unfunded company
- Compose Finance - Warsaw based, 2024 founded, Unfunded company
- Bubbls - United Kingdom based, Unfunded company
- TedhiMedhi Family - India based, Unfunded company
